Latest news

Bioservo engages Erik Penser Bank AB as liquidity provider (regulatory information)

Nomination Committee appointed before the annual general meeting of Bioservo 2022

World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies

Menu

12 Aug, 2021  ·  Regulatory information

Bioservo Technologies AB Interim Report January – June 2021

Second quarter in figures

  • Net sales of SEK 1.0 M (4.8)
  • EBITDA of SEK -9.6 M (-3.8)
  • EBIT of SEK –10.9 M (-4.8)
  • Earnings for the period amounted to SEK -10.9 M (-4.8)
  • Earnings per share before and after dilution amounted to SEK -0.69 (-0.34)
  • Cash flow from operating activities for the period amounted to SEK -10.8 M (-6.0)

First half-year in figures

  • Net sales of SEK 2.5 M (7.8)
  • EBITDA of SEK -17.4 M (-10.4)
  • EBIT of SEK -19.9 M (-12.4)
  • Earnings for the period was SEK -19.9 M (-12.4)
  • Earnings per share before and after dilution amounted to SEK -1.26 (-0.87)
  • Cash flow from operating activities for the period amounted to SEK -18.4 M (-12.3)
  • On 30 of June, cash and cash equivalents were SEK 34.5 M (44.2)

Significant events during the period

  • EUROPE TECHNOLOGIES' GOBIO signed an agreement for purchasing 100 Ironhand® systems at an order value of 4.2 MSEK over a period of ten months. The order will secure the delivery of Ironhand® systems to meet the growing demand in the French market. Bioservo and GOBIO have worked closely together since 2019 and have concluded many successful projects leading to an increasing demand from several industry segments.
  • Bioservo launched a new and improved version of the groundbreaking exoskeleton glove on the 7th of June, 2021 – Ironhand® 2.0, complete with improved activation, better grip, advanced data collection and much more in order to reduce the occurrence of hand-related repetitive strain injuries (RSIs) in industrial workplaces.
  • Loxam Rental France placed orders for 10 Ironhand® 2.0 systems at an order value of 0.6 MSEK. The order is part of the continuing cooperation between Loxam and Bioservo to reduce strain injuries in French industries.

Events after the end of the period

No significant events after the period
 

For further information please contact:

Petter Bäckgren
CEO
petter.backgren@bioservo.com
+46 8 21 17 10

or

Jacob Michlewicz
CFO
jacob.michlewicz@bioservo.com
+46 8 21 17 10

 

Note: This information is such as is required by Bioservo Technologies AB under the EU Market Abuse Regulation. The information was submitted, through the care of the above person, for publication on 12 August 2021 at 08:30 (CET).
 

About Bioservo Technologies

Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy and efficient.

The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength.

Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB, +46(0)8-52800399, info@fnca.se is the company’s Certified Adviser on Nasdaq First North

For more information, please visit www.bioservo.com